Plasma insulin-like growth factor I levels during treatment of congenital adrenal hyperplasia

Anita Cavallo; Richard W. Furlanetto; Walter J. Meyėr

doi:10.1159/000181790

Plasma insulin-like growth factor I levels during treatment of congenital adrenal hyperplasia

Anita Cavallo, Richard W. Furlanetto, Walter J. Meyėr

Psychiatry and Behavioral Sciences

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

We tested the hypotheses that the levels of insulin-like growth factor I (IGF-I) reflect the degree of control during the treatment of patients with congenital adrenal hyperplasia (CAH), and that suppressed IGF-I levels during puberty contribute to decreased adult height. We measured serial IGF-I levels in 26 CAH patients followed over 6 months to 5 years. The control of CAH was variable, with several cases of overtreatment in infancy, and frequent undertreatment in childhood and adolescence. IGF-I levels were quite variable and inconsistent with the control of CAH. Our results suggest that IGF-I levels are not helpful in monitoring CAH patients; IGF-I does not seem to play a role in the growth failure during CAH therapy.

Original language	English (US)
Pages (from-to)	23-26
Number of pages	4
Journal	Hormone Research in Paediatrics
Volume	34
Issue number	1
DOIs	https://doi.org/10.1159/000181790
State	Published - 1990

Keywords

Congenital adrenal hyperplasia
Growth
Insulin-like growth factor I

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1159/000181790

Cite this

@article{1658e0e7f99e423da148b38df1c942eb,

title = "Plasma insulin-like growth factor I levels during treatment of congenital adrenal hyperplasia",

abstract = "We tested the hypotheses that the levels of insulin-like growth factor I (IGF-I) reflect the degree of control during the treatment of patients with congenital adrenal hyperplasia (CAH), and that suppressed IGF-I levels during puberty contribute to decreased adult height. We measured serial IGF-I levels in 26 CAH patients followed over 6 months to 5 years. The control of CAH was variable, with several cases of overtreatment in infancy, and frequent undertreatment in childhood and adolescence. IGF-I levels were quite variable and inconsistent with the control of CAH. Our results suggest that IGF-I levels are not helpful in monitoring CAH patients; IGF-I does not seem to play a role in the growth failure during CAH therapy.",

keywords = "Congenital adrenal hyperplasia, Growth, Insulin-like growth factor I",

author = "Anita Cavallo and Furlanetto, {Richard W.} and Meyėr, {Walter J.}",

year = "1990",

doi = "10.1159/000181790",

language = "English (US)",

volume = "34",

pages = "23--26",

journal = "Hormone Research in Paediatrics",

issn = "1663-2818",

publisher = "S. Karger AG",

number = "1",

}

TY - JOUR

T1 - Plasma insulin-like growth factor I levels during treatment of congenital adrenal hyperplasia

AU - Cavallo, Anita

AU - Furlanetto, Richard W.

AU - Meyėr, Walter J.

PY - 1990

Y1 - 1990

N2 - We tested the hypotheses that the levels of insulin-like growth factor I (IGF-I) reflect the degree of control during the treatment of patients with congenital adrenal hyperplasia (CAH), and that suppressed IGF-I levels during puberty contribute to decreased adult height. We measured serial IGF-I levels in 26 CAH patients followed over 6 months to 5 years. The control of CAH was variable, with several cases of overtreatment in infancy, and frequent undertreatment in childhood and adolescence. IGF-I levels were quite variable and inconsistent with the control of CAH. Our results suggest that IGF-I levels are not helpful in monitoring CAH patients; IGF-I does not seem to play a role in the growth failure during CAH therapy.

AB - We tested the hypotheses that the levels of insulin-like growth factor I (IGF-I) reflect the degree of control during the treatment of patients with congenital adrenal hyperplasia (CAH), and that suppressed IGF-I levels during puberty contribute to decreased adult height. We measured serial IGF-I levels in 26 CAH patients followed over 6 months to 5 years. The control of CAH was variable, with several cases of overtreatment in infancy, and frequent undertreatment in childhood and adolescence. IGF-I levels were quite variable and inconsistent with the control of CAH. Our results suggest that IGF-I levels are not helpful in monitoring CAH patients; IGF-I does not seem to play a role in the growth failure during CAH therapy.

KW - Congenital adrenal hyperplasia

KW - Growth

KW - Insulin-like growth factor I

UR - http://www.scopus.com/inward/record.url?scp=0025630049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025630049&partnerID=8YFLogxK

U2 - 10.1159/000181790

DO - 10.1159/000181790

M3 - Article

C2 - 2074088

AN - SCOPUS:0025630049

SN - 1663-2818

VL - 34

SP - 23

EP - 26

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

IS - 1

ER -

Plasma insulin-like growth factor I levels during treatment of congenital adrenal hyperplasia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this